Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

VANCOUVER, Feb. 14 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced unaudited interim and annual consolidated financial results for the fourth quarter and year ended December 31, 2007. The unaudited financial results are subject to further review and potential adjustment as described under the section "Financial Information".

"Throughout 2007, we continued to build our business with the launch of new products, the receipt of regulatory approvals, and the establishment of new partnerships. We expect our new product pipeline and our portfolio of innovative currently marketed products to provide growth and opportunity in 2008 and beyond," said Dr. William Hunter, President and CEO of Angiotech.

"With our expanded sales and marketing team in place and many of our reorganization activities completed, we believe that we are well positioned to achieve our targets for sales growth and gross margin improvements in the coming year," said Tom Bailey, Chief Financial Officer of Angiotech. "We are confident that during 2008 we will begin to realize returns on the various investments we have made in our business over the last two years."

Fourth Quarter Financial Highlights

- Total revenue, as adjusted for non-recurring items, was

$70.7 million. Total revenue under generally accepted accounting

principles (GAAP) was $71.4 million.

- Net product sales, as adjusted, were $43.5 million, and were derived

primarily from sales of our various single use specialty medical

devices as well as from sales of medical device components to third

parties. Net produ
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... billionth of a meter in size, are around us ... human health, as in some innovative early cancer treatments, ... air pollution, traffic emissions, cosmetics, sunscreen and electronics. , ... Louis, led by Lan Yang, PhD, the Das Family ... and their collaborators at Tsinghua University in China have ...
(Date:9/2/2014)... 2, 2014 Persistence Market Research ... in Pharmaceutical, Biopharma and Life Sciences: North ... the global membrane technology market for pharmaceutical, biopharma and life sciences ... is expected to grow at a CAGR of 9.1% ... of USD 10,886.0 million in 2019. Browse ...
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... Sept. 2, 2014  Synthetic Biologics, Inc. (NYSE ... and drug candidates targeting specific pathogens that cause ... from its final preclinical toxicology study of SYN-004. ... this bridging study was required to move the ... prevent the devastating effects of Clostridium difficile ...
Breaking Biology Technology:Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... KANNAPOLIS, N.C. , May 26 The Immune ... Institute (DHMRI) today announced a collaboration to establish the Center ... H. Murdock Research Institute on the North Carolina Research Campus ... accelerate the discovery and development of new breakthrough treatments for ...
... 26 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.,(NYSE Amex: NBS ) ("NeoStem" or the "Company"), ... the Company,s Chief Executive Officer, Robin Smith , M.D., will,ring the opening bell ... 9:30 a.m. ET on Thursday, May 27, 2010 . , ... "We are honored to be back at ...
... CHICAGO , May 26 Advanced ... ADLS), a biopharmaceutical company engaged in the discovery, development and ... oncology and respiratory diseases, today announced positive results from ... the efficacy of Restanza™ (cethromycin), its novel oral antibiotic, against ...
Cached Biology Technology:The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 2The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 3NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010 2NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010 3NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 2Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 3Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 5
(Date:9/2/2014)... legs and their propensity for eating anything, including each ... now research from North Carolina State University finds that ... the eastern United States. , "The good news is ... of threat to humans," says Dr. Mary Jane Epps, ... of a paper about the research. , The research ...
(Date:9/2/2014)... hot oven, you rapidly pull your hand away. Although ... and responding to such painful stimuli, they are still ... made a surprising discovery about the role of a ... built a structural model of the molecule. These discoveries, ... help direct new strategies to treat pain in people. ...
(Date:9/1/2014)... Is television making us fat? An increasing amount of ... food consumption and a more sedentary lifestyle. Now, a ... TV is alike. Some TV programs might lead people ... find that if you,re watching an action movie while ... Aner Tal, Ph.D. lead author on the new article ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Can action movies make you fat? 2
... have determined the molecular structure of a viral protein, ... virus 5 is part of a family of viruses ... to cold-like illness and is responsible for many hospitalizations ... Jan. 5 by the journal Nature. , Details of ...
... the detailed structure of an essential piece of the ... of human cancers. Understanding the physical shape of the ... it acts to immortalize cells ?and should help scientists ... lack of detailed structural information about the enzyme has ...
... from The Walter and Eliza Hall Institute, using a ... drives the formation of all breast tissue. This discovery ... tissue develops. The identification of the breast stem cell ... cancer develops and how rogue cells evade current therapies. ...
Cached Biology News:Scientists identify molecular structure of key viral protein 2Scientists identify molecular structure of key viral protein 3Scientists identify molecular structure of key viral protein 4Report lists top 20 most-vulnerable African carnivores 2Report lists top 20 most-vulnerable African carnivores 3Report lists top 20 most-vulnerable African carnivores 4Faults in newly discovered breast stem cells may lead to tumours 2